Israeli stem cell therapy company Gamida Cell Ltd. has announced success in the Phase III clinical trial of its treatment for leukemia and lymphoma StemEx. The results show a mortality rate which is 35.5 percent lower for people treated with StemEx, as opposed to people who were not.
Related posts
UN Honors Israeli Food Exec For Sustainability Work
September 26, 2023
Startup Unveils Tech To Speed Up Growth Of Cultivated Meat
September 26, 2023
Israel Invests Millions To Help AI Comprehend Hebrew, Arabic
September 21, 2023
Cybersecurity Startup Cato Raises $238M With $3B Valuation
September 21, 2023
Facebook comments